ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
CLRO
ClearOne, Inc.
There isn't enough reported data to score CLRO yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CLRO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CLRO's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CLRO PE Valuation
CLRO has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CLRO Forward outlook
There aren't enough analyst estimates for CLRO to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over CLRO on earnings, with more consistent year-over-year improvement.
CLRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.34 | +$10.07 |
| Q2 2026 | -$11.00 | -$4.16 |
| Q1 2026 | -$13.30 | -$7.30 |
| Q4 2025 | -$14.77 | -$9.22 |
| Q3 2025 | -$13.41 | -$10.71 |
| Q2 2025 | -$6.84 | -$4.59 |
| Q1 2025 | -$6.00 | -$4.95 |
| Q4 2024 | -$5.55 | -$5.25 |
CLRO lost $3.34 per share over the past year, a smaller loss than the year before.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over CLRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CLRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $1.9M | -17% |
| Q1 2025 | $2.3M | -36% |
| Q4 2024 | $3M | -29% |
| Q3 2024 | $2.5M | -49% |
| Q2 2024 | $2.3M | -58% |
| Q1 2024 | $3.6M | -13% |
| Q4 2023 | $4.2M | +3.3% |
| Q3 2023 | $4.9M | -22% |
CLRO's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -238% | -111 points |
| Q1 2025 | -123% | -66 points |
| Q4 2024 | -68% | -27 points |
| Q3 2024 | -87% | -57 points |
| Q2 2024 | -127% | -102 points |
| Q1 2024 | -57% | -5 points |
| Q4 2023 | -42% | +23 points |
| Q3 2023 | -30% | -12 points |
CLRO's operating margin was −238% last quarter, down 111 points from the same quarter a year ago, near the bottom of its range since 2019.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
CLRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$905K | +$224K |
| Q1 2026 | -$680K | +$776K |
| Q4 2025 | -$11.2M | -$9.7M |
| Q3 2025 | -$754K | +$1.1M |
| Q2 2025 | -$1.1M | +$2.1M |
| Q1 2025 | -$1.5M | -500% |
| Q4 2024 | -$1.6M | -145% |
| Q3 2024 | -$1.9M | -$50K |
CLRO has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over CLRO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CLRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +54% | +942K shares |
| 3 years | +68% | +1.1M shares |
| 5 years | +114% | +1.4M shares |
| Available history | +141% | +1.6M shares |
CLRO has 3M diluted shares, up 54% from a year ago.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLRO Net Leverage
CLRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CLRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.0 | Neutral |
| Stochastic | 18.8 | Oversold |
CLRO's weekly RSI is 46 (neutral) and its Stochastic is 19 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CLRO PE vs Technology Sector
| Metric | CLRO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CLRO has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over CLRO on trend strength, trading above more of its moving averages.
CLRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.70 | 5.9% below |
| 20 week MA | $5.08 | 31% below |
| 50 week MA | $4.74 | 27% below |
| 100 week MA | $5.94 | 41% below |
| 200 week MA | $10.2 | 66% below |
CLRO is in a downtrend: it's below all five of its weekly moving averages, and 66% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CLRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.3 | $37.2 | +42% |
| 2021 | $37.2 | $20.0 | -46% |
| 2022 | $20.0 | $23.1 | +16% |
| 2023 | $23.1 | $16.2 | -30% |
| 2024 | $16.2 | $9.13 | -44% |
| 2025 | $9.13 | $5.33 | -42% |
| 2026 YTD | $5.33 | $3.48 | -35% |
CLRO has the edge over ASTS on returns for 2026, with the stronger performance.